Mr Klaus Martin | Chief Scientific Officer
Polpharma Biologics

Klaus Martin is a Senior Director at Polpharma Biologics and Chief Scientific Officer, leading global late-stage development, strategic marketing and medical affairs functions.
 
Klaus has been working on Biosimilars since 2002. He held global management positions at Sandoz Biopharmaceuticals, first as Global Program Head, e.g. for Sandoz’ filgrastim and rituximab biosimilars, then as Head of Global Pre-clinical and Clinical development and finally as Head of BD&L and Portfolio Management as a member of the Biopharmaceuticals Executive Committee. His teams helped bring to the market Sandoz’ first three biosimilars in the EU, US, Canada and Japan. In 2010 he joined Polpharma, where he set up its global biosimilars business. He is also chair of Medicines for Europe’s Market Access Committee of their Biosimilar Medicines Group.
 
Klaus has an MSc in biochemistry from Freie Universität Berlin and holds a PhD in Pathology from the University of Cambridge. Before joining the pharmaceutical industry, he spent three years as a strategy consultant with OC&C advising international clients in a variety of industries.